No Data
No Data
Zymeworks Engages Investors, Awaits Drug Approval
Zymeworks Announces Participation in Upcoming Investor Conferences
Buy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital Allocation
News Flash: Analysts Just Made A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Forecasts
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO